Question: The Bottom-blown oxygen converter is a furnace developed by the company that is now part of the multinational company of what nationality?

<P0-S0> The Bottom-blown Oxygen Converter or BBOC is a smelting furnace developed by the staff at Britannia Refined Metals Limited (“BRM”), a British subsidiary of MIM Holdings Limited (which is now part of the Glencore group of companies). <P0-S1>  The furnace is currently marketed by Glencore Technology. <P0-S2>  It is a sealed, flat-bottomed furnace mounted on a tilting frame that is used in the recovery of precious metals. <P0-S3>  A key feature is the use of a shrouded lance to inject oxygen through the bottom of the furnace, directly into the precious metals contained in the furnace, to oxidize base metals or other impurities as part of their removal as slag. <SEP> <P1-S0> Glencore plc (an acronym for Global Energy Commodity Resources) is an Anglo–Swiss multinational commodity trading and mining company with headquarters in Baar, Switzerland, and a registered office in Saint Helier, Jersey. <P1-S1>  The current company was created through a merger of Glencore with Xstrata on 2 May 2013. <P1-S2>  s of 2015 , it ranked tenth in the Fortune Global 500 list of the world's largest companies. <P1-S3>  It is the world's third-largest family business. <SEP> <P2-S0> Biopure Corporation was a biopharmaceutical company that specialized in oxygen therapeutics (blood substitutes) for both human and veterinary use. <P2-S1>  The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the body's tissues. <P2-S2>  The oxygen technology uses hemoglobin-based oxygen carrying molecules in solution (HBOCs) to increase oxygen transfer to the tissues. <P2-S3>  The competing companies with Biopure were Allied Pharmaceutical, Northfield Laboratories, Baxter International and Hemosol of Toronto. <P2-S4>  The company developed two products: Hemopure (HBOC-1) <nowiki>[hemoglogin glutamer-250 (bovine)]</nowiki> for human use, and Oxyglobin (HBOC-301) <nowiki>[hemoglobin glutamer-200 (bovine)]</nowiki> for veterinary use. <P2-S5>  As of April 2001, Hemopure was approved for commercial sale in South Africa for treatment of acute anemia in general surgery. <P2-S6>  However, Hemopure has not been able to gain approval in the U.K. or the U.S. because of safety and reliability concerns of the European Commission and the U.S. Food and Drug Administration (FDA) respectively. <P2-S7>  The company formed an agreement with the U.S. Navy to aid in preclinical testing of Hemopure for out-of-hospital treatment of trauma patients in hemorrhagic shock. <P2-S8>  Oxyglobin is the only oxygen therapeutic approved for treatment of canine anemia in both Europe and the U.S. and has treated thousands of cases. <P2-S9>  Unable to obtain FDA approval for Hemopure to date, Biopure ceased operations in 2009 and its assets were purchased by OPK Biotech LLC in September 2009. <P2-S10>  On July 16, 2009 Biopure announced it had filed for bankruptcy protection under Chapter 11, Title 11, United States Code and entered into an agreement with OPK Biotech LLC for the sale of substantially all of its assets . <SEP> <P3-S0> Bristlecone is a supply chain consulting and system Integration multinational company, founded in 1996, with its headquarters situated at San Jose, California. <P3-S1>  The company is a part of $16.9 billion multinational Mahindra Group. <P3-S2>  They have completed more than 300 engagements across 20 different industry verticals till now. <P3-S3>  The company is ranked among the top 10 supply chain system integrators of 2012 in Gartner's Supply Chain System Integrators survey.